NurExone Honored at Berlin and Stockholm Conferences for Breakthrough Contributions to Global Life Sciences and Health InnovationTORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that, further to its press release dated October 8, 2025 (the “October 8 Release”), the Company has received gross proceeds of over C$3.18M through accelerated warrant exercises. The breakdown of the proceeds ...

Core Insights - NurExone Biologic Inc. has been accepted into the BioFab Startup Lab, which is part of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program, aimed at accelerating the commercialization of regenerative innovations [1][2][3] Company Overview - NurExone is a biotechnology company focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data for treating acute spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [6] - The company has established a U.S. subsidiary, Exo-Top Inc., to support its North American growth strategy and plans to create a GMP-compliant facility for naive exosome production [3][6] Industry Context - The BioFab Startup Lab program is federally supported and aims to help early-stage biotechnology companies transition regenerative innovations into scalable manufacturing, reflecting a strategic national capability for the U.S. in biomanufacturing [2][5] - Biofabrication, which involves using living cells and biological materials to manufacture tissues and therapeutic products, is seen as the foundation for next-generation regenerative medicine technologies [4]

Core Insights - NurExone Biologic Inc. is gaining global recognition for its leadership in developing exosome-based regenerative therapies, particularly through the participation of Dr. Ina Sarel at the Precision EV Forum 2025 [1][2][5] Company Overview - NurExone is a biopharmaceutical company focused on exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data for treating acute spinal cord and optic nerve injuries [6] - The company has established Exo-Top Inc., a U.S. subsidiary, to support its North American growth strategy [6] Product Development - ExoPTEN has received Orphan Drug Designation for acute spinal cord injury, facilitating early discussions with the FDA and focusing on innovation and patient safety [3][4] - The product aims to address significant unmet needs in central nervous system repair, demonstrating the ability to restore nerve function and reduce inflammation in preclinical models [4] Regulatory Engagement - Dr. Sarel's presentation at the forum will address regulatory challenges in the clinical development of ExoPTEN, highlighting the company's proactive approach to regulatory approval [2][5] - The invitation to speak at the forum reflects strong international interest in NurExone's lead program and its regulatory strategy [2][5]

TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study was conducted in collaboration with Prof. Ygal Rotenstreich team at the Goldschleger Eye Institute at Sheba Med ...

Accelerates Warrant Expirations and POSITIVE Communications ExtensionTORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study was conducted in collaboration with Prof. ...

Secures Incentive Offer of up to US$255K to Establish Operations in IndianapolisTORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), is planning to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana. The Indian ...

TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to provide the following corporate updates. Israeli Patent Grant Expands Global Jurisdiction The Israel Patent Office has granted the Company’s Patent, entitled “Production of Extracellular Vesicles from Stem Cells.” This grant aligns with NurExone’s recently ...

Core Viewpoint - NurExone Biologic Inc. reported its financial results for Q2 2025, highlighting advancements in its exosome-based therapies for central nervous system injuries and outlining its strategic plans for future clinical trials and manufacturing processes [1][4]. Financial Results - The company raised C$2.3 million through a private placement on April 10, 2025, selling 3,543,238 units at C$0.65 each, with proceeds aimed at working capital and clinical development [6]. - Research and development expenses for Q2 2025 were US$0.70 million, an increase from US$0.51 million in Q2 2024, attributed to higher service provider costs and stock-based compensation [6]. - General and administrative expenses rose to US$1.13 million in Q2 2025 from US$0.81 million in Q2 2024, driven by increased salaries and service provider costs [6]. - The net loss for Q2 2025 was US$1.85 million, compared to a loss of US$1.33 million in the same quarter of 2024 [6]. Corporate Highlights and Business Update - The company plans to initiate a Phase 1/2a trial of its lead product ExoPTEN for acute spinal cord injury in 2026, pending regulatory approvals [6]. - NurExone reported new manufacturing process validation data supporting the scalability and consistency of exosome production, with plans for tech transfer to its U.S. subsidiary Exo-Top for GMP manufacturing [6]. - The company was accepted into the Advanced Regenerative Manufacturing Institute's HealthTech Hub Accelerator to bolster its U.S. growth and manufacturing strategy [6][12]. - NurExone expanded its preclinical data set and engaged in scientific forums to enhance visibility and strategic partnerships [12]. Management Commentary - The CEO emphasized the importance of de-risking scale and quality through a validation-led manufacturing process and advancing U.S. tech transfer planning [7]. - The CFO noted that the April 2025 Offering strengthened the company's cash position to support ExoPTEN and align spending with milestone objectives [8]. About the Company - NurExone Biologic Inc. is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product ExoPTEN targeting acute spinal cord and optic nerve injuries, which represent multi-billion-dollar markets [9]. - The company has established Exo-Top Inc. as a U.S. subsidiary to anchor its North American activities and growth strategy [9].

Core Viewpoint - NurExone Biologic Inc. has successfully closed a private placement and announced promising preclinical imaging results for its lead product ExoPTEN, which shows potential for spinal cord repair following injury [1][10][14]. Company Developments - The company closed a non-brokered private placement of 1,258,072 units at C$0.62 per unit, raising gross proceeds of C$780,004.64, intended for working capital [10][11]. - NurExone is preparing for its first-in-human clinical trial of ExoPTEN, pending regulatory approval [4][14]. Product and Research Insights - Preclinical imaging analysis indicates that ExoPTEN-treated animals exhibited more organized spinal cord tissue compared to untreated controls, with 100% of higher-dose group animals regaining motor function [2][3]. - MRI-Diffusion Tensor Imaging (MRI-DTI) results show that treated spinal cords had greater structural integrity, with higher Fractional Anisotropy (FA) values and lower Mean Diffusivity (MD) values near the injury site, suggesting healthier tissue architecture [5][6][8][9]. - The imaging results support the neuroprotective and regeneration-promoting activity of ExoPTEN in spinal cord injury [3][15]. Market Context - Spinal cord injuries present significant healthcare and economic challenges, with current treatments primarily focusing on stabilization rather than tissue repair. ExoPTEN aims to address this unmet need by supporting nerve repair and restoring function [4][14]. - The market for spinal cord injury treatments is substantial, with NurExone's lead product positioned in a multi-billion-dollar market [14].

Core Insights - NurExone Biologic Inc. announced that its exosomes outperformed a recognized commercial industry standard in key healing tasks such as nerve repair, wound repair, immune system modulation, and tissue rebuilding, indicating broad potential in therapeutic and aesthetic markets [1][6] Group 1: Exosome Performance - Independent study results showed NurExone's exosomes exhibit approximately 1.8-fold higher neurological potential, nearly double the anti-inflammatory activity, and a two-fold increase in tissue-regeneration and wound-healing signals compared to commercial benchmarks [4] - The exosomes produced by NurExone's U.S. subsidiary, ExoTOP Inc., are expected to deliver more than twice the wound-healing signals than the industry benchmark, suggesting applications in aesthetic skin rejuvenation, wound care, and orthopedic tissue repair [2][4] Group 2: Production and Technology - NurExone's exosomes are produced from a proprietary master cell bank, ensuring high-performance and reproducibility essential for clinical translation and future patient use [3] - The exosomes are enriched with microRNAs that support key healing tasks, as confirmed by a comprehensive analysis performed by TAmiRNA, an ISO13485-certified molecular-diagnostics laboratory [2][7] Group 3: Market Potential and Strategy - The company is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data for treating acute spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [8] - ExoTOP is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine as production scales in the U.S. [2][8]